Search

Public safety organizations around the world started migrating toward Long-Term Evolution (LTE) networks to support the increasing needs for video and data. To address the unique voice communication requirements of first responders, the 3rd Generation Partnership Project (3GPP) introduced new capabilities that aim at providing similar functionalities as the traditional Land Mobile Radio (LMR) systems, namely, Direct Mode communication and mission critical push-to-talk (MCPTT). Direct Mode communication, also called Proximity Services (ProSe), allows public safety users to communicate directly with each other regardless of the network status. MCPTT was the first mission critical service, and first application, standardized by 3GPP to provide both on- and off-network voice capability. Assessing the performance of those capabilities is critical to accelerate their deployment and adoption by first responders. In this study, we evaluate the performance of an off-network mode MCPTT device over ProSe by focusing on the access time, a measure of the delay incurred before a user can talk. We develop analytical models for various types of calls and verify the accuracy of the predicted access time using ns-3 simulations. We perform sensitivity analysis to show the validity of the models for various scenarios. Finally, we show how the models can be used to guide parameter configuration for both MCPTT and ProSe to optimize the performance.

The recent developments of synchronized cardiac MRI are a unique opportunity for the radiology community to integrate cardiac imaging. This educational aticle aims to help radiologists and technicians to obtain cardiac planes comparable to those of cardiac ultrasound and gated SPECT. Of course, cardiac planes described herein for MRI also apply to multi-detector CT.

One hundred thirty-two women between the ages of 19 and 50, with various forms of benign breast diseases received 1 mg promegestone, or 0.5 mg promegestone, or 10 mg lynestrenol daily (double-blind), for 15 days per cycle, during three cycles. The groups were identical before treatment, with the exception of a longer history of mastodynia and mastopathies in the 1 mg promegestone group than in the lynestrenol group ( P = 0.04) and a greater proportion of mastosis zones in the lynestrenol group as compared to the 0.500 mg promegestone group ( P = 0.05). The effectiveness of lynestrenol both in terms of symptomatology (evaluated as good or excellent in 66.6% of the cases) and of clinical observations (evaluated as good or excellent in 59% of the cases) is not significantly different statistically from that of promegestone at 1 mg, whose effectiveness on symptomatology was good or excellent in 65.9% and 57.1% of the cases, respectively, or from that of promegestone at 0.5 mg/day (with 65% and 51.3% effectiveness, respectively). Clinical tolerance was rated good or excellent for 73.9% of the women on 1 mg promegestone and for 59.5% of the women on 0.500 mg promegestone, compared to 66.7% of the women on lynestrenol. No statistically significant difference was observed, neither between lynestrenol and promegestone 1 mg nor between lynestrenol and promegestone 0.5 mg. This study shows a clear improvement in functional and physical signs in patients treated with promegestone. Promegestone's efficacy is close to that of lynestrenol, a norsteroidal progestin. A dosage of 0.5 mg promegestone from the 11th to the 25th day of the cycle may be given, and this dosage may be adapted to take into account clinical response.

On a routine basis we performed systematic molecular screening for FGFR3 and TP53 mutations in 121 bladder tumors. We then specifically analyzed the predictive value of the recurrence of FGFR3 and TP53 genotypes in superficial lesions.The FGFR3 gene was analyzed by direct sequencing of exons 7, 10 and 15, whereas TP53 status was determined using the p53 functional assay in yeast.We identified a missense FGFR3 mutation in 66% of pTa, 26% of pT1 and 12% of pT2 tumors. Of activating FGFR3 mutations 54% and 85% were found in low G1 and intermediate G2 grade tumors, respectively, but in only 20% of high grade G3 tumors. We detected inactivating TP53 mutations in 10% of pTa, 42% of pT1 and 58% of pT2 tumors. Moreover, TP53 mutations were found only in 23% of grade G1 and 3% of grade G2 tumors but in 44% of high grade G3 tumors. When the 2 genotypes were combined, we observed that 58% of pTa tumors had the (mutant FGFR3, WT TP53) genotype, whereas 58% of invasive lesions harbored the inverse genotype (WT FGFR3, mutant TP53). The (mutant FGFR3, WT TP53) genotype and the (WT FGFR3, mutant TP53) genotype were detected in 23% and 38% of pT1G3 tumors, respectively. In the subgroup of 92 patients with superficial pTa-T1 bladder tumors we did not find that the TP53 or FGFR3 genotype alone or combined had a predictive value for tumor recurrence.Our data again represent solid proof for the pivotal role of FGFR3 and TP53 mutations in superficial and invasive bladder tumors, respectively. However, other molecular markers should be identified for borderline pT1G3 bladder tumors, which are probably at the crossroads of these 2 distinct molecular pathways.

WN-gate, p-channel AlGaAs-GaAs heterostructure insulated-gate field-effect transistors (HIGFETs) fabricated on a metalorganic vapor-phase epitaxy (MOVPE) wafer are discussed. A self-aligned Mg ion implantation (80 keV, 6*10/sup 13/ cm/sup -2/) annealed at 850 degrees C in an arsine atmosphere and the control of the SiO/sub 2/ sidewall dimensions allow the fabrication of p-channel HIGFETs with a gate length smaller than 0.5 mu m with low subthreshold current. P-channel HIGFETs with 0.4- mu m gate lengths exhibit extrinsic transconductances as high as 127 mS/mm at 77 K and 54 mS/mm at 300 K. >

III–V integrated circuits associating on one hand a photoconductive detector and on the other hand an MSM photodetector with HIGFETs for optical clock distribution are presented. First, static and dynamic properties of these planar photodetectors are studied, taking into account the main characteristics of their structures (ion implantation for photoconductive detectors and AlxGa1−xAs upper layer with x=0.45 for MSM photodetectors). Secondly, their integration with a III–V digital IC is reported. This IC includes a divider by two and its operation has been investigated up to 1.2 GHz.

An interdigitated GaAIAs/GaAs metal-semiconductor-metal photodetector designed to be fully integrable with HIGFET-based digital integrated circuits and which exhibits a dark current as low as 100 pA at 10 V bias voltage is presented. Static and dynamic responsivities are reported, as well as noise properties. Photocurrents (for bias voltage higher than 4 V) comparable to those measured with a pin photodiode, and a shot noise cutoff frequency in excess of 13 GHz were recorded.